A fragment-based drug discovery approach to the synthesis and identification of small molecule inhibitors of bovine carbonic anhydrase II (bCA II) is described. The classical bCA II recognition fragment is an aromatic sulfonamide (ArSO 2 NH 2 ) moiety. This fragment was incorporated into a scaffold building block, which was subsequently derivatized by dynamic combinatorial chemistry utilizing alkene cross metathesis as the reversible reaction. Screening against bCA II was then carried out and the results allowed determination of the relative bCA II binding affinities of the cross metathesis products that contained the ArSO 2 NH 2 fragment. A bCA II competitive binding assay validated these results with a representative number of pure compounds. The results for screening, without prior isolation of the active constituent, were in full agreement with those obtained for equilibrium dissociation constants (Ki's) of pure compounds. Some of these compounds exhibited Ki's in the low nanomolar range. Heterogeneous catalysis was shown to be very effective in this drug discovery application of dynamic combinatorial chemistry.
Introduction
Dynamic combinatorial chemistry (DCC) exploits reversible covalent reactions to synthesize libraries of molecules. Unlike conventional synthesis, DCC proceeds not to generate high yielding pure compounds, but rather to access diversity and enable amplification of the 'best binder' by interaction of dynamic combinatorial library (DCL) constituents with a target in a self-screening protocol.
1,2 Drug discovery applications of DCC require reaction conditions that do not disrupt the target's function or structure. Specifically, this means that (i) reaction at a biologically relevant temperature (ii) compatibility with aqueous media (iii) reaction at (close to) physiological pH, and (iv) compatibility with the target functional groups, are each necessary to enable ligand amplification from DCLs when generated in the presence of a protein target. 1, 2 The concept of a pre-equilibrated DCL (pDCL) has also been described wherein the DCL is prepared in the absence of the protein target, and the library screened post-synthesis for identification of components with affinity for the protein target. 3, 4 This approach may be applied when the stringent criteria just described cannot be met. While the pDCL approach does not permit the amplification of the best binder(s) it does still benefit from the ease and potentially greater diversity generated in DCC synthesis owing to reversible covalent reactions. There are now multiple examples of drug discovery from both DCLs generated in the presence of a protein target (through ligand amplification) and pDCLs generated prior to screening against the protein target. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Each of these reported examples has drawn upon a pre-existing knowledge of the protein-small molecule system and collectively they represent a special application of fragment-based drug discovery optimisation methodology. 15 This manuscript describes our efforts towards fragment-based drug discovery of carbonic anhydrase II (CA II) inhibitors utilizing DCC with alkene cross metathesis (CM)
as the reversible reaction. CM has often been cited alongside transimination (of imines, oximes and hydrazones) and disulfide exchange as a promising reversible reaction for drug discovery applications of DCC. While examples of imine exchange, and to a lesser extent disulfide exchange, now abound this is not so for CM. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] There is only one reported example of CM operating close to the stringent criteria described above wherein Nicolaou and coworkers employed a biphasic reaction medium to link vancomycin monomers by CM in the presence of D-Ala-D-Ala type targets. 16 The biphasic system was necessary as commercially available CM catalysts are not sufficiently water soluble to operate in a completely aqueous reaction medium. There are no reported DCC drug discovery applications of CM where the target is a protein. 
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Insert Figure 1 The alkene metathesis reaction, using the carbene ruthenium catalysts developed by Grubbs, is well studied for conventional organic chemistry applications. 22, 23 The CM variant of this reaction generates alkenes that are either homodimers (from self-CM) or heterodimers. As well both trans or cis geometry about the newly formed alkene bonds is possible (Fig. 2 ).
Despite the variable product distributions possible from CM the general utility of this reaction has recently been extended by the development of a model that classifies alkene reactivity towards CM. 24 Classifications range from Type I alkenes (those which undergo rapid self-CM) through to Type IV alkenes (those which are inert to CM). Based on this classification potentially large differences in the CM rate from structurally diverse alkene building blocks can be expected. This paper demonstrates that this need not translate into complications for DCC applications of CM that take advantage of the reversible nature of the reaction.
Insert Figure 2 
Results and Discussion

Design of building blocks
Building block 1, an allyl ester benzene sulfonamide, was prepared specifically as a scaffold building block to facilitate this study (Fig. 3A) . The dual functionality of 1, possessing an aromatic sulfonamide moiety and an allyl substituent, was designed to support both fragmentbased drug discovery (through provision of the bCA II recognition fragment for reliable bCA II affinity) and evaluation of CM chemistry for DCC (through provision of a terminal alkene functionality). Ten additional building blocks A-J (each containing a terminal alkene functionality and therefore able to undergo CM with 1) were also synthesized (Fig. 3B ).
Building blocks A-G were derived from amino acids and contained either a tertiary Nallylamide moiety (A-C) or a vinyl benzene moiety (D-G). Building blocks I and J were aromatic allyl esters, while H was an aliphatic allyl ester. A-J were selected to introduce diversity onto the scaffold building block 1 and so enable exploration of potential secondary recognition interactions that may complement the well known bCA II interaction with an aromatic sulfonamide fragment.
Insert Figure 3 
Cross metathesis chemistry
Initial experiments were designed to demonstrate both the reversibility of the CM reaction and its utility for DCC. Heterogeneous catalysis has not before been applied to DCC, but appears well suited to facilitate the reaction start-stop requirements of drug discovery applications: simple filtration to remove the catalyst (stop sequence), and addition/re-addition of catalyst (start sequence). In principle the start-stop sequence could be repeated many times without interfering with the overall DCL composition, unlike homogeneous catalysis that necessitates the 'permanent' addition of reagents to the DCL to achieve the same outcome. 3C ). 25 The characterization data for 2ab (prepared by CM) was consistent with that for the predominantly trans isomer 2a. CM of 2a (25 mM) with building block A (50 mM) resulted in formation of heterodimer 1A, as evidenced in the mass spectrum ( Fig 
Preparation and screening of pDCLs for bCA II affinity
To confirm the premise that the aromatic sulfonamide moiety was indeed a prerequisite for bCA II recognition we first screened the simplest possible pDCLs generated by CM of our 11 building blocks. These reactions each contained one building block as starting material (1, A-J) and the only products were those from self-CM, being 2ab and AA-JJ (Fig. 5A ). As these simple pDCLs were devoid of the heterodimer products 1A-1J, they also served as convenient controls for background bCA II affinity in subsequent DCLs that contained the homodimers 2ab and AA-JJ, as well as heterodimers 1A-1J. The pDCL reactions were prepared similarly to that described above. The 12 pDCLs (11 from building blocks and one control containing only immobilized metathesis catalyst) were then assessed for bCA II enzyme binding by a fluorescence-based assay. This assay relies on the competition between the ligand 5-(dimethylamino)-1-napthalenesulfonamide (DNSA) and the test compounds for the active site of bCA II. 17, 26, 27 A complete description of the assay procedure has been described elsewhere. 28 Screening of each pDCL at 1 µM and 10 µM (based on theoretical CM product concentration) was carried out. The results for the 10 µM screen, expressed as percentage retention of the DNSA control binding, are presented in Figure 5B . With the exception of the pDCL from 1, which displaced 88% of DNSA, none of the pDCLs (including the control) contained molecules that displaced DNSA from the binding site of bCA II (100% DNSA retention). These results provided confirmation that the aromatic sulfonamide was a necessary fragment for bCA II recognition with only the self-CM product 2ab (a bis-sulfonamide), and not self-CM products AA through to JJ (devoid of the bCA II recognition fragment), demonstrating affinity for bCA II. The remainder of this paper describes our DCC strategy for determining the relative bCA II affinities of the aromatic sulfonamide containing CM heterodimers 1A-1J in the presence of the common background of 2ab and the inactive homodimers AA-JJ.
Insert Figure 5
The previous section demonstrated that only the symmetrical bis-sulfonamide 2ab would be responsible for the background bCA II binding affinity response in pDCLs generated from CM of 1 with A-J. To minimize the background bCA II affinity of 2ab in DCLs we elected to use 10 equivalents of A-J as the CM partner of 1 (Fig. 6A ). The effect of this biased stoichiometry was to increase the proportion of the heterodimer CM products 1A-1J relative to the self-CM product 2ab compared for when equimolar amounts of 1 and A-J were reacted. 24 The negative ion ESI MS analysis revealed that the CM of 1 with A produced the homodimer 2ab (<5%) but predominantly the hetereodimer 1A (~90%), similarly for CM of 1 with building blocks B-J. As 1A-1J each contained the aromatic sulfonamide fragment they were expected to exhibit some affinity for bCA II. The collective library was then screened at 1 µM and 10 µM, the results for the 10 µM screen, expressed as percentage retention of the DNSA from bCA II, are displayed in Figure 6B . The homodimerization self-CM reaction of 1 (to generate 2ab) is included in Figure 6B for comparison.
Insert Figure 6
The bCA II screening results presented in Figure 6B demonstrated that the CM products 1A-1J exhibited variable affinity for bCA II. These compounds each contained the core bCA II As the bCA II screen was performed directly on the crude library, without isolation of the CM heterodimers 1A-1J, we needed to validate that the bCA II affinity was due to these heterodimers and not just the reduced presence of the bis-sulfonamide 2ab. We proceeded to synthesize the trans isomers of the ester building block series 1H-1J as pure entities. A determination of the bCA II equilibrium dissociation constants (Ki's) was then carried out and results for affinities 2ab, 2a, 2b, 1H, 1I and 1J are presented in Table 1 
Synthetic Chemistry
Conclusion
This study has demonstrated that the application of fragment-based drug discovery to inhibitors of bCA II is effective utilizing a pre-equilibrated DCC strategy together with CM as the reversible reaction. Specifically, the results demonstrated that with appropriate control experiments confidence in the observed trend of bCA II affinity obtained when assaying the library without purification was indeed a reflection of actual bCA II affinity. This result is significant as synthesis and purification of CM products is typically cumbersome, and if it can be avoided at the early stage of the drug discovery timeline (which is where DCC typically is placed) then it is highly advantageous from the viewpoint of both cost and required effort.
Finally, heterogeneous catalysis has not before been applied to DCC. Herein we have demonstrated the convenience and benefits of heterogenous catalysis (over homogeneous catalysis) to facilitate the reaction start-stop requirements for drug discovery applications of DCC: simple filtration to remove the catalyst (stop sequence), and addition/re-addition of catalyst (start sequence).
Experimental
Chemistry
All synthetic reagents and anhydrous solvents used were purchased from commercial sources.
Grubbs first-generation catalyst was available as an immobilized reagent (Fluka catalogue number 91501, on a polystyrene support, loading 0.1 mmol/g) while Grubbs secondgeneration catalyst was purchased from Sigma-Aldrich (catalogue number 569747). All solvents used for chromatography were Lab-Scan HPLC grade. Flash chromatography was performed on E. Merck Silica gel GF-60 grade silica (particle size 0.0400 -0.063 mm).
Analytical thin-layer chromatography was performed on 0.25 E Merck silica-gel plates (60-F-254 Characterization data was consistent with the trans product 2a. 25 
Synthesis of methyl-3-methyl-2-[(4-vinylbenzoyl)amino]butanoate (D) as a representative of building blocks D-G.
A suspension of 4-vinylbenzoic acid (100 mg, 0.67 mmol), EDC ( 
Synthesis of (2E)-4-(acyloxy)but-2-enyl-4-(aminosulfonyl)benzoate (1H)
To a solution of (2E)-butene-1,4-diol (0.5 g, 5.7 mmol ) in pyridine (10 mL) was added acetic anhydride (0.756 g, 7.4 mmol) dropwise over 6 h. The reaction was stirred at room temperature for 24 h and then concentrated. The residue was redissolved in CH 2 Cl 2 (25 mL), washed with 1N HCl (2 x 20 mL), saturated NaHCO 3 (20 mL) and saturated brine (20 mL).
The organic phase was dried over MgSO 4 
Synthesis of (2E)-4-(biphenyloxy)but-2-enyl-4-(aminosulfonyl)benzoate (1J)
Biphenylcarbonyl chloride (0.125 g, 0.575 mmol) was added portionwise over 2 h to a solution of (2E)-butene-1,4-diol (1.20 g, 2.3 mmol) in pyridine (5 mL). The solution was stirred at room temperature for 72 h and then concentrated. The residue was redissolved in m/z over 4 s and multiple scans were summed to obtain the final spectrum, which was processed using MassLynx V 3.4 software. Sample preparation for the bCA II enzyme assay was performed by serial dilution of the pDCL with water.
Biological assay
Compounds 2ab, 1H, 1I, 1J and all pDCL reactions were assessed for their ability to inhibit 
